Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02818699 · ClinicalTrials.gov registry record · NA
Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects
A NA study, sponsored by Tufts University.
- Completed
- Registry status
- NA
- Development phase
- 65
- Enrollment target
NCT02818699 is a NA study that has completed, run by Tufts University. The registered enrollment target is 65 participants.
The verdict
NCT02818699, a NA study, has completed, sponsored by Tufts University.
- COMPLETED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this clinical study is to determine the effect and safety of long-term intake of enzymatically modified isoquercitrin (EMIQ), a natural plant product on body fat loss in obese and overweight individuals.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT EMIQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2018-09-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02818699
The ClinicalTrials.gov registry entry for NCT02818699 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02818699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02818699 about?
NCT02818699 is a clinical study titled "Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects". The purpose of this clinical study is to determine the effect and safety of long-term intake of enzymatically modified isoquercitrin (EMIQ), a natural plant product on body fat loss in obese and overweight individuals.
What is the current status of trial NCT02818699?
This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2016-08-01. Estimated completion is 2018-09-14.
What interventions are being tested in trial NCT02818699?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), EMIQ (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02818699?
This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.